

Clonazepam Rosemont Oral Solutions

0.5mg/5mL & 2mg/5mL

Instructions for administration via nasogastric (NG) or percutaneous endoscopic gastrostomy (PEG) tubes:

Clonazepam Rosemont Oral Solution is suitable for use with the following types of NG and PEG tubes:

Material	External Bore Size (Fr Unit)	Internal Diameter (mm)	Maximum Length (cm)
Silicone	6	1.0	125
	10	2.0	125
Polyurethane	8	1.5	100
	12	2.6	75
	18	4.0	75

This product is not compatible with PVC or polystyrene and therefore should not be used with NG or PEG tubes made from these materials

Care should be taken during administration due to the oily nature of the product.

It is recommended to administer the dose prior to delivering feed through the NG or PEG tube and to follow the instruction below:

Ensure that the enteral feeding tube is free from obstruction before administration.

1. Flush the enteral tube with water. A minimum flush volume of 10mL is required.

2. Administer the required dose of Clonazepam Rosemont Oral Solution with a suitable measuring device.

3) Flush the enteral tube again by either of the methods below:

i) Flush the enteral tube 3 consecutive times, using a minimum volume of 5mL of water each time.

ii) Flush the enteral tube using a minimum volume of 5mL of water and then immediately deliver a minimum of 10mL of feed.

Healthcare professionals should be aware that if the instructions above cannot be followed (e.g. longer or wider tubes are used or in specific clinical situations) there is a risk of under dosing (up to 15%) as the oily medicine may adsorb to the wall of the feeding tube. Extra flushing with water or feed may combat this. In these situations the patient should be monitored closely.

Any unused product or waste material should be disposed of in accordance with local requirements.



DTM057.1 July 2020

Rosemont Pharmaceuticals Ltd. Rosemont House, Yorkdale Industrial Park, Braithwaite Street, Leeds LS11 9XE **T** +44 (0)113 244 1400 **F** +44 (0)113 245 3567 **E** infodesk@rosemontpharma.com **Sales/ Customer Service:** **T** +44 (0) 113 244 1999 **F** +44 (0) 113 246 0738 **W** www.rosemontpharma.com

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard Adverse events should also be reported to Rosemont Pharmaceuticals Ltd on 0113 244 1400.